Stocktube video
14/11/2012

ImmunoCellular Therapeutics fully funded to end of Phase II trials

View full size
Additional Information
Market: NYSE
Sector: Pharmaceuticals & Biotechnology
EPIC: IMUC
1 year chart
Deal IMUC Tax Free*
*subject to change and depends on individual circumstances.
1 day chart
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmunoCellular Therapeutics
www.imuc.com
Deal ImmunoCellular Therapeutics Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies...

Read more
Pdf

ImmunoCellular Therapeutics CEO to speak at Phacilitate Immunotherapy Leaders' Forum

May 08 2012, 6:23pm

ImmunoCellular Therapeutics (OTC:IMUC) said Tuesday that its CEO, Manish Singh, will speak at the Phacilitate Immunotherapy Leaders' Forum 2012, in Barcelona, Spain.

Dr. Singh will speak at the forum taking place from May 9-11, and will deliver the Chair’s introductory presentation titled: "A retrospective of the past 15 years of novel immunotherapy products— from Rituxan™ to Adcetris™," to begin at 9:00 am local time on Wednesday May 9th.

The Phacilitate Immunotherapy Leaders' Forum is an annual gathering place for senior executives and scientists driving the development of immunotherapies. The event is focused on overcoming the challenges involved in bringing these technologies to the market.

ImmunoCellular is a clinical-stage biotech company based in Los Angeles. The company focuses on the development of new immune-based products in the treatment and diagnosis of brain and other cancers.

A phase II trial recently started on the company's leading product candidate, ICT-107, a dendritic cell-based vaccine that targets multiple tumour-associated antigens for glioblastoma, an aggressive form of brain cancer.

This is done by removing dendritic cells from a patient, loading them with the tumour-related antigens, and re-injecting them back into the patient's body to trigger an immune response against cancer cells exhibiting these antigens.

Rather than simply targeting a single tumour-specific antigen, IMUC’s vaccine tracks multiple different antigens found on cancer stem cells.

Cancer stem cells are thought to be the originators of common tumour cells, and lead to cancer’s re-growth after chemotherapy. It is believed that destroying the cancer stem cells will allow for longer survival, without relapse.

Details of the conference may be found at http://www.phacilitate.co.uk/event.php?eid=12&pid=282

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.